152 related articles for article (PubMed ID: 32180508)
1. Comparison of rituximab originator (MabThera
Perez T; Rico A; Boutière C; Maarouf A; Roudot M; Honoré S; Pelletier J; Bertault-Peres P; Audoin B
Mult Scler; 2021 Apr; 27(4):585-592. PubMed ID: 32180508
[TBL] [Abstract][Full Text] [Related]
2. Comparison of outcomes using the rituximab originator MabThera with the biosimilar Truxima in patients with ANCA-associated vasculitis.
Antonelou M; Abro A; Heath R; Iacovou A; Ashley C; Caplan J; Morgan MD; Logan S; Harper L; Salama AD
Scand J Rheumatol; 2022 Mar; 51(2):135-141. PubMed ID: 34474634
[TBL] [Abstract][Full Text] [Related]
3. Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator.
Kwon HC; Kim MK; Song JJ; Park YB; Lee SW
Yonsei Med J; 2020 Aug; 61(8):712-719. PubMed ID: 32734735
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura.
Stubbs MJ; Low R; McGuckin S; Newton R; Thomas M; Westwood JP; Shah R; Cheesman S; Scully MA
Br J Haematol; 2019 Jun; 185(5):912-917. PubMed ID: 30919938
[TBL] [Abstract][Full Text] [Related]
5. Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience.
Bahap-Kara M; Duran E; Bayraktar-Ekincioglu A; Karadag O
Intern Emerg Med; 2023 Apr; 18(3):791-799. PubMed ID: 36826744
[TBL] [Abstract][Full Text] [Related]
6. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden.
Di Giuseppe D; Lindstrom U; Bower H; Delcoigne B; Frisell T; Chatzidionysiou K; Sjöwall C; Lindqvist E; Askling J
Rheumatology (Oxford); 2022 Aug; 61(9):3596-3605. PubMed ID: 34919663
[TBL] [Abstract][Full Text] [Related]
8. Safety of switching between rituximab biosimilars in onco-hematology.
Urru SAM; Spila Alegiani S; Guella A; Traversa G; Campomori A
Sci Rep; 2021 Mar; 11(1):5956. PubMed ID: 33727667
[TBL] [Abstract][Full Text] [Related]
9. The clinical outcomes of rituximab biosimilar CT-P10 (Truxima
Lee K; Ha JY; Jung AR; Lee YS; Lee SW; Ryu JS; Chae EJ; Kim KW; Huh J; Park CS; Yoon DH; Suh C
Leuk Lymphoma; 2020 Jul; 61(7):1575-1583. PubMed ID: 32290739
[TBL] [Abstract][Full Text] [Related]
10. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan.
Halawah HH; Alkhatib NS; Almutairi AR; Saleh M; Halloush SS; Rashdan O; Masadh L; Abusara OH; Abraham I
J Med Econ; 2023; 26(1):835-842. PubMed ID: 37318242
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
Bae SC; Lee YH
Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
13. Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System.
Jourdain H; Hoisnard L; Sbidian E; Zureik M
BioDrugs; 2023 May; 37(3):397-407. PubMed ID: 36877448
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera
Sharman JP; Liberati AM; Ishizawa K; Khan T; Robbins J; Alcasid A; Rosenberg JA; Aurer I
BioDrugs; 2020 Apr; 34(2):171-181. PubMed ID: 31820339
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study.
Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L
Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207
[TBL] [Abstract][Full Text] [Related]
16. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
17. Real-world intensive safety monitoring of biosimilars rituximab and trastuzumab in a Portuguese oncology hospital.
Mendes D; Abrantes J; Rigueiro G; Pais AF; Penedones A; Alves C; Batel-Marques F
J Oncol Pharm Pract; 2021 Sep; 27(6):1432-1438. PubMed ID: 32936721
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.
Coiffier B
Expert Rev Clin Pharmacol; 2017 Sep; 10(9):923-933. PubMed ID: 28766389
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.
Rioufol C; Salles G
Expert Rev Anticancer Ther; 2015 May; 15(5):569-78. PubMed ID: 25818308
[TBL] [Abstract][Full Text] [Related]
20. A novel approach to support implementation of biosimilars within a UK tertiary hospital.
Saxby K; Sanghvi S; Bodalia PN; Ferner RE; Leandro M; Urquhart R; Sofat R
Br J Clin Pharmacol; 2020 Jan; 86(1):23-28. PubMed ID: 31663154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
